Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice
Recombinant Mycobacterium bovis BCG producing the circumsporozoite protein of Plasmodium falciparum FCC-1/HN strain induces strong immune responses in BALB/c mice
复制标题
DOI：
10.1016/s1383-5769(01)00094-0
复制
发表时间：
2002-03-01
影响因子：
1.9
通讯作者：
Chen, YT
中科院分区：
文献类型：
--
作者：
Zheng, CF;Xie, PM;Chen, YT
目前针对结核病的疫苗，牛分枝杆菌菌株卡介苗（BCG），作为用于表达和递送保护性重组抗原的活的先天免疫原性疫苗载体提供了潜在的优势。疟疾是人类最严重的寄生虫病之一，特别是在发展中国家。目前还没有有效的疫苗。然而，环子孢子蛋白（CSP）是目前正在进行临床试验的疟疾疫苗候选者。本文分析了热休克蛋白70启动子调控下表达恶性疟原虫CSP的重组卡介苗（rBCG）疫苗（BCG-CSP）在BALB/c小鼠体内的免疫应答。淋巴细胞对恶性疟原虫可溶性抗原的增殖反应显著高于BCG组和生理盐水对照组; rBCG组和BCG组对疟疾抗原的细胞因子（IFN-γ和IL-2）产生显著高于生理盐水对照组。还表征了CSP针对恶性疟原虫抗原的特异性IgG抗体应答。加强免疫可增强小鼠细胞因子的产生、脾淋巴细胞的增殖反应和卡介菌多糖核酸疫苗抗体滴度。研究结果表明，生产CSP的rBCG疫苗是一种适合在非人灵长类动物中进行进一步评价的疫苗。(C)2002爱思唯尔科学爱尔兰有限公司保留所有权利。
The current vaccine against tuberculosis, Mycobacterium bovis strain bacillue Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for expression and delivery of protective recombinant antigens. Malaria is one of the severest parasitic diseases in humans especially in the developing world. No efficacious vaccine is currently available. However, circumsporozoite protein (CSP) is a malaria vaccine candidate currently undergoing clinical trials. We analyzed the immune response to recombinant BCG (rBCG) vaccine expressing Plasmodium falciparum CSP (BCG-CSP) under the control of heat shock protein 70 promoter in BALB/c mice. The lymphocytes proliferative response to P. falciparum soluble antigen was significantly higher than those in the groups of BCG and normal saline, and the production of cytokines (IFN-gamma and IL-2) in response to malaria antigen was significantly higher in rBCG and BCG groups than control group of normal saline. A specific IgG antibody response against P. falciparum antigen of CSP was also characterized. The booster injection could enhance the production of cytokine, proliferation responses of spleen lymphocytes and the antibodies titer of BCG-CSP. The results in the study demonstrated that rBCG vaccine producing CSP is an appropriate vaccine for further evaluation in non-human primates. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.